CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib

Cyclin D‐CDK4/6 are the first CDK complexes to be activated in the G1 phase in response to oncogenic pathways. The specific CDK4/6 inhibitor PD0332991 (palbociclib) was recently approved by the FDA and EMA for treatment of advanced ER‐positive breast tumors. Unfortunately, no reliable predictive too...

Descripción completa

Detalles Bibliográficos
Autores principales: Raspé, Eric, Coulonval, Katia, Pita, Jaime M, Paternot, Sabine, Rothé, Françoise, Twyffels, Laure, Brohée, Sylvain, Craciun, Ligia, Larsimont, Denis, Kruys, Véronique, Sandras, Flavienne, Salmon, Isabelle, Van Laere, Steven, Piccart, Martine, Ignatiadis, Michail, Sotiriou, Christos, Roger, Pierre P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538335/
https://www.ncbi.nlm.nih.gov/pubmed/28566333
http://dx.doi.org/10.15252/emmm.201607084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538335/
https://www.ncbi.nlm.nih.gov/pubmed/28566333
http://dx.doi.org/10.15252/emmm.201607084

Ejemplares similares